NervGen Pharma Corp.

TSXV:NGEN Stock Report

Market Cap: CA$210.9m

NervGen Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

TSXV:NGEN Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
28 Mar 24BuyCA$20,001Glenn IvesIndividual8,511CA$2.35
28 Mar 24BuyCA$103,564William AdamsIndividual44,070CA$2.35
28 Mar 24BuyCA$23,500Randall KayeIndividual10,000CA$2.35
28 Mar 24BuyCA$60,000Harold PunnettIndividual25,532CA$2.35
28 Mar 24BuyCA$13,531Krista McKerracherIndividual5,758CA$2.35
28 Mar 24BuyCA$338,299Michael KellyIndividual143,957CA$2.35
28 Mar 24BuyCA$102,857Gianni RuffoloIndividual43,380CA$3.95
28 Mar 24BuyCA$6,766,000The Paul And Phyllis Fireman Charitable Foundation, Endowment ArmCompany2,879,149CA$2.35
28 Mar 24BuyCA$47,000William RadvakIndividual20,000CA$2.35
11 Mar 24SellCA$450,000Brian BayleyIndividual150,000CA$3.00
08 Jan 24BuyCA$5,318Krista McKerracherIndividual2,000CA$2.66

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of NGEN?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,981,9852.82%
Institutions2,923,5494.16%
VC/PE Firms10,000,00014.2%
General Public55,402,61578.8%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18%.

Top Shareholders

Top 12 shareholders own 21.2% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
14.2%
PFP Biosciences Holdings
10,000,000CA$30.0m-22.4%no data
4.1%
The Paul And Phyllis Fireman Charitable Foundation, Endowment Arm
2,879,149CA$8.6m0%no data
1.6%
Harold Punnett
1,125,532CA$3.4m0%no data
0.57%
Brian Bayley
400,000CA$1.2m0%no data
0.22%
William Adams
155,820CA$467.5k0%no data
0.2%
Michael Kelly
143,957CA$431.9k0%no data
0.1%
Gianni Ruffolo
70,407CA$211.2k0%no data
0.083%
Glenn Ives
58,511CA$175.5k0%no data
0.063%
Timelo Investment Management Inc.
44,400CA$133.2k0%0.19%
0.014%
Randall Kaye
10,000CA$30.0k0%no data
0.014%
Adam Rogers
10,000CA$30.0k0%no data
0.011%
Krista McKerracher
7,758CA$23.3k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:44
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NervGen Pharma Corp. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Chelsea StellickiA Capital Markets
Scott McAuleyParadigm Capital, Inc.
Justin KeywoodStifel Canada